Patients receiving bicalutamide (80 mg) combination therapy are significantly more likely to achieve (prostate-specific antigen) PSA levels ≤ 4 ng/ml and have higher overall tumor-response rates than those receiving LHRH-A alone [42]. Here, KLK3 is linked to neoplasm.